We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current QNCX market cap is 79.34M. The company's latest EPS is USD -1.2498 and P/E is -1.42.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.22M | -28.19M | -5.86M | -12.01M | -14.86M |
| Net Income | -11.15M | -27.73M | -5.49M | -12.46M | -15.03M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -78.89M | -90.32M | -52.02M | -34.62M | -57.29M |
| Net Income | -76.85M | -89.95M | -51.66M | -31.39M | -56.83M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 159.29M | 134.83M | 126.52M | 114.48M | 107.09M |
| Total Liabilities | 85.12M | 87.86M | 81.59M | 84.33M | 88.51M |
| Total Equity | 74.18M | 46.97M | 44.93M | 30.15M | 18.58M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 189.47M | 133.23M | 103.91M | 167.9M | 114.48M |
| Total Liabilities | 17.2M | 14.64M | 3.32M | 82.82M | 84.33M |
| Total Equity | 172.26M | 118.59M | 100.59M | 85.08M | 30.15M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -8.35M | -17.09M | -24.35M | -31.9M | -9.6M |
| Investing | 8.91M | 3.94M | 11.04M | 21.91M | 10.9M |
| Financing | 190k | 225k | -4.78M | -4.78M | 87k |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.82M | -62.93M | -44.04M | -18.29M | -31.9M |
| Investing | -52.43M | 58.95M | 18M | -5.76M | 21.91M |
| Financing | 118.88M | 6.81M | 707k | 143k | -4.78M |
| Market Cap | 79.34M |
| Price to Earnings Ratio | -1.42 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 12.96 |
| Price to Book Ratio | 2.67 |
| Dividend Yield | - |
| Shares Outstanding | 45.47M |
| Average Volume (1 week) | 317.67k |
| Average Volume (1 Month) | 309.71k |
| 52 Week Change | 132.67% |
| 52 Week High | 2.45 |
| 52 Week Low | 0.5116 |
| Spread (Intraday) | 0.03 (1.7%) |
| Company Name | Quince Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://quincetx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
